Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2

Within a year after the emergence of SARS-CoV-2, several vaccines had been developed, clinically evaluated, proven to be efficacious in preventing symptomatic disease, and licensed for global use. The remaining questions about the vaccines concern the duration of protection offered by vaccination an...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller-Hilke, Brigitte, Mai, Franz, Müller, Michael, Volzke, Johann, Reisinger, Emil C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880180/
https://www.ncbi.nlm.nih.gov/pubmed/35214780
http://dx.doi.org/10.3390/vaccines10020322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880180/
https://www.ncbi.nlm.nih.gov/pubmed/35214780
http://dx.doi.org/10.3390/vaccines10020322

Ejemplares similares